Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00692055 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations
A Phase 1 study of Arthritis, sponsored by POZEN.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00692055: Completed Phase 1 study of Arthritis, sponsored by POZEN.
NCT00692055 is a Phase 1 study of Arthritis that has completed, run by POZEN. The registered enrollment target is 30 participants, below the 4,509-participant average among 48 other Arthritis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00692055, a Phase 1 study of Arthritis, has completed, sponsored by POZEN.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
We will evaluate the bioavailability of naproxen 375 mg in two formulations
Conditions Studied
Interventions
- DRUG Naproxen
- DRUG PN400
Study Locations (1)
Texas
- - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
What the finished NCT00692055 record still lists
NCT00692055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 4,509-participant average among 48 other Arthritis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Naproxen is the first listed.
NCT00692055 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00692055 about?
NCT00692055 is a clinical study titled "Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations". We will evaluate the bioavailability of naproxen 375 mg in two formulations
What is the current status of trial NCT00692055?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-06. Estimated completion is 2008-07.
What conditions does trial NCT00692055 study?
This clinical trial studies the following conditions: Arthritis.
What interventions are being tested in trial NCT00692055?
The interventions under investigation include: Naproxen (DRUG), PN400 (DRUG).
Who is sponsoring clinical trial NCT00692055?
This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00692055 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00692055's enrollment target sits among peer trials
30 37th of 48 higher than 12 of 48 other Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of the Walk With Ease Program for Fall Prevention
RECRUITING · Phase 1
-
Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects
COMPLETED · Phase 1
-
Sustained Acoustic Medicine (SAM) Combined With a Diclofenac Ultrasound Coupling Patch for Knee Osteoarthritis
COMPLETED · Phase 1
-
Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis
COMPLETED · Phase 1
-
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
RECRUITING
-
Expanding Exercise Programming for Veterans Through Telehealth
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia